2026-04-17T12:10:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2159202025-11-19T10:41:20Zcom_2072_1057col_2072_478815col_2072_478917

00925njm 22002777a 4500 dc Bertran-Mostazo, Andrea author Putriute, Gabrielé author Álvarez-Berbel, Irene author Busquets i Viñas, Ma. Antonia author Galdeano Cantador, Carlos author Espargaró Colomé, Alba author Sabaté Lagunas, Raimon author 2024-10-21T10:49:16Z 2024-10-21T10:49:16Z 2024-03-04 2024-10-21T10:49:16Z <p>Proximity-induced pharmacology (PIP) for amyloid-related diseases is a cutting-edge</p><p>approach to treating conditions such as Alzheimer’s disease and other forms of dementia. By bringing</p><p>small molecules close to amyloid-related proteins, these molecules can induce a plethora of effects</p><p>that can break down pathogenic proteins and reduce the buildup of plaques. One of the most</p><p>promising aspects of this drug discovery modality is that it can be used to target specific types of</p><p>amyloid proteins, such as the beta-amyloid protein that is commonly associated with Alzheimer’s</p><p>disease. This level of specificity could allow for more targeted and effective treatments. With ongoing</p><p>research and development, it is hoped that these treatments can be refined and optimized to provide</p><p>even greater benefits to patients. As our understanding of the underlying mechanisms of these</p><p>diseases continues to grow, proximity-induced pharmacology treatments may become an increasingly</p><p>important tool in the fight against dementia and other related conditions.</p> Malalties neurodegeneratives Amiloïdosi Disseny de medicaments Neurodegenerative Diseases Amyloidosis Drug design Proximity-induced pharmacology for amyloid-related diseases<br />